{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030387","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.475442+00:00","generated_at":"2026-06-08T21:47:49.055538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OPKO Q3 net loss $84.5M; revenues flat; BARDA awards $59M contract for ModeX","bullets":["Net loss $84.5M ($0.11/sh) vs $86.1M; operating loss improved to $64.4M from $87.8M YoY.","Diagnostics revenue $131.7M (-8% YoY); operating loss improved 41% to $29.1M on cost cuts.","Pharmaceuticals revenue $40.7M (+26% YoY) driven by international sales; RAYALDEE up to $7.3M.","ModeX awarded $59M BARDA contract for multispecific antibodies; up to $109M in milestones.","NGENLA approved in 48 markets; U.S. gross profit sharing began August 2023; cash $138.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030387","json":"https://secwatch.observer/filing/0001437749-23-030387.json","markdown":"https://secwatch.observer/filing/0001437749-23-030387.md","text":"https://secwatch.observer/filing/0001437749-23-030387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774923030387/0001437749-23-030387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774923030387/opk20231024_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:47:49.055538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"472cb2f1b76961db7442d51a792fa40914ea6dad","claim":"OPKO HEALTH, INC. reported the quarter ended September 30, 2023 results: revenue $178.6 million.","evidence_excerpt":"Consolidated total revenues for the third quarter of 2023 were $178.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774923030387/0001437749-23-030387-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$178.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}